Jubilant Pharmova Limited (NSE:JUBLPHARMA)

India flag India · Delayed Price · Currency is INR
966.95
-24.10 (-2.43%)
Feb 21, 2025, 3:30 PM IST
60.94%
Market Cap 153.26B
Revenue (ttm) 70.64B
Net Income (ttm) 6.27B
Shares Out n/a
EPS (ttm) 39.50
PE Ratio 24.44
Forward PE n/a
Dividend 5.00 (0.52%)
Ex-Dividend Date Aug 2, 2024
Volume 142,603
Average Volume 415,420
Open 980.00
Previous Close 991.05
Day's Range 961.05 - 1,011.50
52-Week Range 538.05 - 1,309.90
Beta 1.61
RSI 46.96
Earnings Date Jan 31, 2025

About Jubilant Pharmova

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary ... [Read more]

Sector Healthcare
Founded 1978
Employees 5,399
Stock Exchange National Stock Exchange of India
Ticker Symbol JUBLPHARMA
Full Company Profile

Financial Performance

Financial Statements

News

Jubilant to buy 40% in Coke bottler's parent for 10k cr

Jubilant Bhartia Group is set to acquire a 40% stake in Hindustan Coca-Cola Holdings (HCCH), the parent company of India's largest Coca-Cola bottler, for over Rs 10,000 crore. This investment reflects...

2 months ago - The Times of India

Bernstein maintains Outperform rating on Jubilant Foodworks, highlights three pillars to achieve $10 billion market cap

Bernstein maintains an Outperform (O-P) rating on Jubilant Foodworks, with a target price of ₹700, highlighting three critical growth pillars needed for Jubilant to achieve a market cap of ₹80,000 cro...

3 months ago - Business Upturn

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC: EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial...

3 months ago - Benzinga

CLSA maintains ‘Underperform’ rating on Jubilant FoodWorks with target price of Rs 445, expecting 26% downside

CLSA has reiterated its ‘Underperform’ rating on Jubilant FoodWorks, setting a target price of ₹445, indicating a potential 26% downside from the current market price (CMP) of ₹602.60. Key insights fr...

3 months ago - Business Upturn

Jefferies maintains ‘Buy’ rating on Jubilant FoodWorks with target price of Rs 880, expecting 46% upside

Jefferies has reiterated its ‘Buy’ rating on Jubilant FoodWorks, setting a target price of ₹880, indicating a potential 46% upside from the current market price (CMP) of ₹602.60. Key takeaways from Je...

3 months ago - Business Upturn

Morgan Stanley maintains ‘Equal-weight’ rating on Jubilant FoodWorks with target price of Rs 620

Morgan Stanley has reiterated its ‘Equal-weight’ rating on Jubilant FoodWorks, setting a target price of ₹620, indicating a modest upside from the current market price (CMP) of ₹602.60. Key insights f...

3 months ago - Business Upturn

Stocks to Watch: RIL, Adani Enterprises, BEL, GAIL, Kaynes Technology, Lupin, Jubilant Pharma, Zomato and morein focus today (Sept 30, 2024)

Indian benchmark indices ended lower on September 27, with the Nifty slipping below 26,200. The BSE Midcap and Smallcap indices remained relatively flat. The top losers on the Nifty included Power Gri...

5 months ago - Business Upturn